Emerging anti-inflammatory strategies for COPD

被引:99
作者
Cazzola, Mario [1 ,2 ]
Page, Clive P. [4 ]
Calzetta, Luigino [2 ]
Matera, M. Gabriella [3 ]
机构
[1] Univ Roma Tor Vergata, Dept Syst Med, Unit Resp Clin Pharmacol, I-00133 Rome, Italy
[2] San Raffaele Pisana Hosp, IRCCS, Dept Pulm Rehabil, Rome, Italy
[3] Univ Naples 2, Pharmacol Unit, Dept Expt Med, Naples, Italy
[4] Kings Coll London, Inst Pharmaceut Sci, Sackler Inst Pulm Pharmacol, London WC2R 2LS, England
关键词
Chronic obstructive pulmonary disease; targeted therapy; therapeutic interventions; treatment of chronic obstructive pulmonary disease; OBSTRUCTIVE PULMONARY-DISEASE; PLACEBO-CONTROLLED TRIAL; LEUKOTRIENE B-4; AIRWAY INFLAMMATION; CHEMOKINE RECEPTORS; P38; MAPK; PHOSPHODIESTERASE-4; INHIBITORS; NEUTROPHIL CHEMOTAXIS; MACROLIDE ANTIBIOTICS; PREVENTS EMPHYSEMA;
D O I
10.1183/09031936.00213711
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The hallmark of chronic obstructive pulmonary disease (COPD) is an enhanced or abnormal inflammatory immune response of the lungs to inhaled particles and gases, usually from cigarette smoke, characterised by increased numbers of neutrophils, activated macrophages and activated T-lymphocytes (Tc1 and Th1 cells). Therefore, suppression of the inflammatory response is a logical approach to the treatment of COPD. Despite the inflammatory nature of COPD, currently available anti-inflammatory therapies provide little or no benefit in COPD patients and may have detrimental effects. For this reason, there is an urgent need to discover effective and safe anti-inflammatory treatments that might prevent the relentless progression of the disease. In recent years, attention has largely been focused on inhibition of recruitment and activation of inflammatory cells, and on antagonism of their products. In this review, we put together a summary of the state-of-the-art development of clearly and/or potentially useful antiinflamThatory strategies in COPD.
引用
收藏
页码:724 / 741
页数:18
相关论文
共 153 条
[41]   Signalling pathways - Kinase regulation in inflammatory response [J].
Delhase, M ;
Li, NX ;
Karin, M .
NATURE, 2000, 406 (6794) :367-368
[42]   Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: A pilot study [J].
Dentener, Mieke A. ;
Creutzberg, Eva C. ;
Pennings, Herman-Jan ;
Rijkers, Ger T. ;
Mercken, Evi ;
Wouters, Emiel F. M. .
RESPIRATION, 2008, 76 (03) :275-282
[43]   Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells:: Possible role in the signaling pathway that regulates nuclear factor-κB activation [J].
Desaki, M ;
Okazaki, H ;
Sunazuka, T ;
Omura, S ;
Yamamoto, K ;
Takizawa, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) :1581-1585
[44]   The PPAR alpha-leukotriene B-4 pathway to inflammation control [J].
Devchand, PR ;
Keller, H ;
Peters, JM ;
Vazquez, M ;
Gonzalez, FJ ;
Wahli, W .
NATURE, 1996, 384 (6604) :39-43
[45]   PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease [J].
Diamant, Zuzana ;
Spina, Domenico .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2011, 24 (04) :353-360
[46]   Attacking the multi-tiered proteolytic pathology of COPD: New insights from basic and translational studies [J].
Djekic, Uros V. ;
Gaggar, Amit ;
Weathington, Nathaniel M. .
PHARMACOLOGY & THERAPEUTICS, 2009, 121 (02) :132-146
[47]   Associations between statins and COPD: A systematic review [J].
Dobler C.C. ;
Wong K.K. ;
Marks G.B. .
BMC Pulmonary Medicine, 9 (1)
[48]   Therapy for chronic obstructive pulmonary disease in the 21st century [J].
Donnelly, LE ;
Rogers, DF .
DRUGS, 2003, 63 (19) :1973-1998
[49]   Aerosolized Phosphoinositide 3-Kinase γ/δ Inhibitor TG100-115 [3-[2,4-Diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a Therapeutic Candidate for Asthma and Chronic Obstructive Pulmonary Disease [J].
Doukas, John ;
Eide, Lisa ;
Stebbins, Karin ;
Racanelli-Layton, Adrienne ;
Dellamary, Luis ;
Martin, Michael ;
Dneprovskaia, Elena ;
Noronha, Glenn ;
Soll, Richard ;
Wrasidlo, Wolfgang ;
Acevedo, Lisette M. ;
Cheresh, David A. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 328 (03) :758-765
[50]  
Duraisamy S, 2008, EXPERT OPIN THER TAR, V12, P921, DOI [10.1517/14728222.12.8.921, 10.1517/14728222.12.8.921 ]